Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: Experience from a nationwide high-volume centre in China

BJU International

Volumn 112, Issue 7, 2013, Pages 917-924

  Chen, Xiao Peng ^a   Xiong, Geng Yan ^a   Li, Xue Song ^a   Matin, Surena F ^b   Garcia, Maurice ^c   Fang, Dong ^a   Wang, Tian Yu ^a   Yu, Wei ^a   Gong, Kan ^a   Song, Yi ^a   He, Zhi Song ^a   He, Qun ^a   Zhou, Li Qun ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

non organ confined disease; upper urinary tract carcinoma; urothelial carcinoma; worse pathological outcome

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER LOCALIZATION; CANCER PROGNOSIS; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPATHOLOGY; FEMALE; GENDER BIAS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDRONEPHROSIS; KIDNEY PELVIS; MAJOR CLINICAL STUDY; MALE; MUSCLE INVASIVE BLADDER CANCER; NEPHROURETERECTOMY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; TRANSITIONAL CELL CARCINOMA; TUMOR INVASION;

NON-ORGAN-CONFINED DISEASE; UPPER URINARY TRACT CARCINOMA; UROTHELIAL CARCINOMA; WORSE PATHOLOGICAL OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CHINA; FEMALE; HUMANS; HYDRONEPHROSIS; KIDNEY NEOPLASMS; KIDNEY PELVIS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; URETERAL NEOPLASMS; YOUNG ADULT;

EID: 84886094225     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12238     Document Type: Article

References (29)

1. Rouprêt M, Zigeuner R, Palou J, et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 Update. Eur Urol 2011; 59: 584-594
2. Chen GL, Bagley DH,. Ureteroscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. J Urol 2000; 164: 1173-1176
3. Gadzinski AJ, Roberts WW, Faerber GJ, Wolf JS Jr,. Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol 2010; 183: 2148-2153
4. Lughezzani G, Jeldres C, Isbarn H, et al. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Eur J Cancer 2009; 45: 3291-3297
5. Li CC, Chang TH, Wu WJ, et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol 2008; 54: 1127-1135
6. Roscigno M, Shariat SF, Margulis V, et al. Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol 2009; 181: 2482-2489
7. Miyao N, Masumori N, Takahashi A, et al. Lymph node metastasis in patients with carcinomas of the renal pelvis and ureter. Eur Urol 1998; 33: 180-185
8. Brausi MA, Gavioli M, De Luca G, et al. Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrative transitional cell carcinoma (TCC) of the upper urinary tract: impact on survival. Eur Urol 2007; 52: 1414-1420
9. Roscigno M, Cozzarini C, Bertini R, et al. Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract. Eur Urol 2008; 53: 794-802
10. Matin SF, Margulis V, Kamat A, et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 2010; 116: 3127-3134
11. Youssef RF, Shariat SF, Lotan Y, et al. Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU Int 2011; 108: 1286-1291
12. Isbarn H, Jeldres C, Shariat SF, et al. Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. J Urol 2009; 182: 2177-2181
13. Lughezzani G, Sun M, Perrotte P, et al. Gender-related differences in patients with stage I to III upper tract urothelial carcinoma: results from the Surveillance, Epidemiology, and End Results Database. Urology 2010; 75: 321-327
14. Mungan NA, Kiemeney LA, van Dijck JA, et al. Gender differences in stage distribution of bladder cancer. Urology 2000; 55: 368-371
15. Yu W, Zhao YY, Shen Q, et al. Gender-related differences in pathological characteristics of upper urinary tract urothelial carcinoma: analysis of 597 cases. Beijing Da Xue Xue Bao 2011; 43: 522-524
16. Chou YH, Huang CH,. Unusual clinical presentation of upper urothelial carcinoma in Taiwan. Cancer 1999; 85: 1342-1344
17. Yang MH, Chen KK, Yen CC, et al. Unusually high incidence of upper tract urothelial carcinoma in Taiwan. Urology 2002; 59: 681-687
18. Wu MC, Wu ZD, eds. Huang Jia Si Surgery, 7th edn. Beijing: People's Medical Publishing House, 2008: 2360
19. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: 2937-2944
20. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266
21. Chromecki TF, Cha EK, Fajkovic H, et al. The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol 2012; 61: 245-253
22. Lai MN, Wang SM, Chen PC, et al. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 2010; 102: 179-186
23. Lai MN, Lai JN, Chen PC, et al. Increased risks of chronic kidney disease associated with prescribed Chinese herbal products suspected to contain aristolochic acid. Nephrology 2009; 14: 227-234
24. Debelle FD, Vanherweghem JL, Nortier JL,. Aristolochic acid nephropathy: a worldwide problem. Kidney Int 2008; 74: 158-169
25. Margulis V, Youssef RF, Karakiewicz PI, et al. Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol 2010; 184: 453-458
26. Raman JD, Ng CK, Scherr DS, et al. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol 2010; 57: 1072-1079
27. Fritsche HM, Novara G, Burger M, et al. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. Urol Oncol 2012; 30: 666-672
28. Favaretto RL, Shariat SF, Savage C, et al. Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU Int 2012; 109: 77-82
29. Messer JC, Terrell JD, Herman MP, et al. Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urol Oncol 2011 Sep 7. [Epub ahead of print]. DOI: 10.1016/j.urolonc.2011.07.011